Analyst Price Targets — UTHR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 5:23 pm | Andrew Fein | H.C. Wainwright | $600.00 | $508.47 | StreetInsider | United Therapeutics Corp. (UTHR) PT Raised to $600 at H.C. Wainwright |
| January 6, 2026 1:38 pm | — | UBS | $645.00 | $506.79 | TheFly | United Therapeutics price target raised to $645 from $600 at UBS |
| November 19, 2025 9:24 am | Eun Yang | Jefferies | $575.00 | $476.59 | StreetInsider | Jefferies Reiterates Buy Rating on United Therapeutics Corp. (UTHR) |
| October 30, 2025 1:34 pm | Andrew Fein | H.C. Wainwright | $525.00 | $449.76 | TheFly | United Therapeutics price target raised to $525 from $500 at H.C. Wainwright |
| October 30, 2025 1:32 pm | Lisa Walter | RBC Capital | $587.00 | $449.76 | TheFly | United Therapeutics price target raised to $587 from $569 at RBC Capital |
| October 29, 2025 4:13 pm | Terrance Flynn | Morgan Stanley | $447.00 | $449.70 | StreetInsider | United Therapeutics (UTHR) PT Raised to $447 at Morgan Stanley |
| October 10, 2025 12:07 pm | Terence Flynn | Morgan Stanley | $435.00 | $445.38 | TheFly | United Therapeutics price target raised to $435 from $328 at Morgan Stanley |
| September 29, 2025 10:28 am | — | UBS | $580.00 | $432.66 | TheFly | United Therapeutics price target raised to $580 from $560 at UBS |
| September 26, 2025 9:16 am | — | RBC Capital | $569.00 | $427.16 | TheFly | United Therapeutics initiated with an Outperform at RBC Capital |
| September 10, 2025 11:58 am | Olivia Brayer | Cantor Fitzgerald | $525.00 | $396.50 | TheFly | United Therapeutics price target raised to $525 from $405 at Cantor Fitzgerald |
Latest News for UTHR
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide a company overview and update on Monday, March 9, 2026, from 1:00 to 1:30 p.m. EDT, at the Leerink Global Healthcare Conference in Miami Beach. The presentation can be accessed via a live webcast on the…
United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension Transcript
United Therapeutics said on Monday its experimental pill for a type of blood pressure disorder met all the main and secondary goals of a late-stage study.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its long-term pivotal phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55% compared with placebo in patients with PAH (hazard ratio 0.45, 95% CI [0.33-0.62]; p
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for UTHR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.